Sarah Pirio Richardson1, Ashley R Wegele2, Betty Skipper2, Amanda Deligtisch2, H A Jinnah2. 1. From the Departments of Neurology (S.P.R., A.R.W., A.D.) and Family and Community Medicine (B.S.), University of New Mexico Health Sciences Center, Albuquerque; and Departments of Neurology, Human Genetics, and Pediatrics (H.A.J.), Emory University School of Medicine, Atlanta, GA. spiriorichardson@salud.unm.edu. 2. From the Departments of Neurology (S.P.R., A.R.W., A.D.) and Family and Community Medicine (B.S.), University of New Mexico Health Sciences Center, Albuquerque; and Departments of Neurology, Human Genetics, and Pediatrics (H.A.J.), Emory University School of Medicine, Atlanta, GA.
Abstract
OBJECTIVE: To determine the frequency of medication use in patients with dystonia enrolled in an international biorepository study. METHODS: In a cross-sectional analysis, we included 2,026 participants enrolled at 37 sites in the United States, Canada, Europe, and Australia through Project 1 of the Dystonia Coalition, an international biorepository study. The primary aim was to assess the frequency of medication classes recommended for treating patients with dystonia, and the secondary aim was to compare characteristics (disease type, age, sex, duration of disease, comorbid conditions, severity). RESULTS: Querying the database for the presence of any medication for dystonia used (includes both injectable and oral therapy), we found 73% using medications (n = 1,488) and 27% using no dystonia medications (n = 538). Furthermore, 61% of the total sample used botulinum toxin (BoNT) therapy alone or in combination. Differences were found in medication use patterns by dystonia type, with the lowest oral medication use in focal dystonia and highest use in generalized dystonia; by region, with highest BoNT therapy rate reported in Italy and the lowest in the Northeast region of the United States; and by focal dystonia subtype, with highest BoNT therapy alone in blepharospasm and spasmodic dysphonia (49%) and lowest in other cranial dystonia (32%). CONCLUSIONS: The majority of patients with dystonia enrolled in the Dystonia Coalition Project 1 were using medications to treat their dystonia. Overall, a complex picture of medication use patterns emerged, with factors such as region, disease duration, type of dystonia, disease severity, and psychiatric comorbidities all playing a significant role.
OBJECTIVE: To determine the frequency of medication use in patients with dystonia enrolled in an international biorepository study. METHODS: In a cross-sectional analysis, we included 2,026 participants enrolled at 37 sites in the United States, Canada, Europe, and Australia through Project 1 of the Dystonia Coalition, an international biorepository study. The primary aim was to assess the frequency of medication classes recommended for treating patients with dystonia, and the secondary aim was to compare characteristics (disease type, age, sex, duration of disease, comorbid conditions, severity). RESULTS: Querying the database for the presence of any medication for dystonia used (includes both injectable and oral therapy), we found 73% using medications (n = 1,488) and 27% using no dystonia medications (n = 538). Furthermore, 61% of the total sample used botulinum toxin (BoNT) therapy alone or in combination. Differences were found in medication use patterns by dystonia type, with the lowest oral medication use in focal dystonia and highest use in generalized dystonia; by region, with highest BoNT therapy rate reported in Italy and the lowest in the Northeast region of the United States; and by focal dystonia subtype, with highest BoNT therapy alone in blepharospasm and spasmodic dysphonia (49%) and lowest in other cranial dystonia (32%). CONCLUSIONS: The majority of patients with dystonia enrolled in the Dystonia Coalition Project 1 were using medications to treat their dystonia. Overall, a complex picture of medication use patterns emerged, with factors such as region, disease duration, type of dystonia, disease severity, and psychiatric comorbidities all playing a significant role.
Authors: J W Brans; R Lindeboom; J W Snoek; M J Zwarts; T W van Weerden; E R Brunt; J J van Hilten; W van der Kamp; M H Prins; J D Speelman Journal: Neurology Date: 1996-04 Impact factor: 9.910
Authors: Dirk Dressler; Eckart Altenmueller; Roongroj Bhidayasiri; Saeed Bohlega; Pedro Chana; Tae Mo Chung; Steven Frucht; Pedro J Garcia-Ruiz; Alain Kaelin; Ryuji Kaji; Petr Kanovsky; Rainer Laskawi; Federico Micheli; Olga Orlova; Maja Relja; Raymond Rosales; Jaroslaw Slawek; Sofia Timerbaeva; Thomas T Warner; Fereshte Adib Saberi Journal: J Neural Transm (Vienna) Date: 2015-09-14 Impact factor: 3.575
Authors: Aristide Merola; Alok K Dwivedi; Aasef G Shaikh; Tamour Khan Tareen; Gustavo A Da Prat; Marcelo A Kauffman; Jennie Hampf; Abhimanyu Mahajan; Luca Marsili; Joseph Jankovic; Cynthia L Comella; Brian D Berman; Joel S Perlmutter; Hyder A Jinnah; Alberto J Espay Journal: J Neurol Date: 2019-04-26 Impact factor: 4.849
Authors: Abhimanyu Mahajan; Joseph Jankovic; Laura Marsh; Achint Patel; H A Jinnah; Cynthia Comella; Richard Barbano; Joel Perlmutter; Neepa Patel Journal: J Neurol Date: 2018-03-22 Impact factor: 4.849
Authors: Maja Rogić Vidaković; Ivana Gunjača; Josipa Bukić; Vana Košta; Joško Šoda; Ivan Konstantinović; Braco Bošković; Irena Bilić; Nikolina Režić Mužinić Journal: J Clin Med Date: 2022-06-15 Impact factor: 4.964
Authors: Kristina Simonyan; Julie Barkmeier-Kraemer; Andrew Blitzer; Mark Hallett; John F Houde; Teresa Jacobson Kimberley; Laurie J Ozelius; Michael J Pitman; Robert Mark Richardson; Nutan Sharma; Kristine Tanner Journal: Neurology Date: 2021-04-15 Impact factor: 11.800
Authors: Susan H Fox; Matthew Swan; Hyder A Jinnah; Maria E T de Freitas; Lais M de Oliveira; Duha Al-Shorafat; Hubert H Fernandez; Katie Kompoliti; Cynthia Comella Journal: Mov Disord Clin Pract Date: 2021-05-13